NO20052408L - Farmasoytisk formulering av olanzapin - Google Patents

Farmasoytisk formulering av olanzapin

Info

Publication number
NO20052408L
NO20052408L NO20052408A NO20052408A NO20052408L NO 20052408 L NO20052408 L NO 20052408L NO 20052408 A NO20052408 A NO 20052408A NO 20052408 A NO20052408 A NO 20052408A NO 20052408 L NO20052408 L NO 20052408L
Authority
NO
Norway
Prior art keywords
olanzapine
pharmaceutical formulation
monosaccharide
oligosaccharide
polysaccharide
Prior art date
Application number
NO20052408A
Other languages
English (en)
Other versions
NO20052408D0 (no
Inventor
Stanka Perc
Ivanka Banko
Ivanka Kolenc
Original Assignee
Krka Tovarna Zdravil Dd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32173824&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20052408(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Krka Tovarna Zdravil Dd filed Critical Krka Tovarna Zdravil Dd
Publication of NO20052408D0 publication Critical patent/NO20052408D0/no
Publication of NO20052408L publication Critical patent/NO20052408L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

En farmasøytisk formulering omfattende en homogen blanding av (a) olanzapin eller et farmasøytisk akseptabelt salt av derme som aktiv ingrediens, (b) et monosakkarid og/eller ohgosakkarid, (c) et polysakkarid og eventuelt ytterligere ingredienser.
NO20052408A 2002-10-18 2005-05-13 Farmasoytisk formulering av olanzapin NO20052408L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200200255A SI21303A (sl) 2002-10-18 2002-10-18 Farmacevtska formulacija olanzapina
PCT/SI2003/000036 WO2004035027A1 (en) 2002-10-18 2003-10-16 Pharmaceutical formulation of olanzapine

Publications (2)

Publication Number Publication Date
NO20052408D0 NO20052408D0 (no) 2005-05-13
NO20052408L true NO20052408L (no) 2005-07-04

Family

ID=32173824

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052408A NO20052408L (no) 2002-10-18 2005-05-13 Farmasoytisk formulering av olanzapin

Country Status (18)

Country Link
US (2) US20050288276A1 (no)
EP (1) EP1558219B1 (no)
AT (1) ATE374600T1 (no)
AU (1) AU2003269792A1 (no)
CA (1) CA2502582C (no)
CY (1) CY1107819T1 (no)
DE (1) DE60316714T2 (no)
DK (1) DK1558219T3 (no)
EA (1) EA008516B1 (no)
ES (1) ES2295626T3 (no)
HR (1) HRP20050342B1 (no)
NO (1) NO20052408L (no)
PL (1) PL206217B1 (no)
PT (1) PT1558219E (no)
RS (1) RS51488B (no)
SI (2) SI21303A (no)
UA (1) UA89349C2 (no)
WO (1) WO2004035027A1 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006018318A1 (en) * 2004-08-18 2006-02-23 Synthon B.V. Liquid paroxetine compositions
CZ297214B6 (cs) * 2005-02-02 2006-10-11 Zentiva, A. S. Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
GB0522474D0 (en) * 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
GB0522473D0 (en) * 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
ES2279715B1 (es) 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
WO2007134845A2 (en) * 2006-05-18 2007-11-29 Synthon B.V. Olanzapine pharmaceutical composition
CL2007002807A1 (es) * 2006-09-29 2008-04-11 Synthon Bv Composicion farmaceutica en estado solido que comprende olanzapina o una sal farmaceuticamente aceptable de la misma y lactosa anhidra; tableta farmaceutica oral; procedimiento de preparacion de dicha tableta, util en el tratamiento de la esquizofren
WO2012014012A1 (es) * 2010-07-27 2012-02-02 Laboratorios Andrómaco S.A. Procedimiento para preparar comprimidos de disolucion rapida oral que comprenden la forma i de olanzapina, los comprimidos obtenidos y su uso para el tratamiento de la esquizofrenia.
WO2012153347A2 (en) 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
WO2013066280A1 (en) * 2011-10-31 2013-05-10 Mahmut Bilgic Water soluble antipsychotic formulations
CN103919782B (zh) * 2013-01-15 2016-12-28 天津药物研究院有限公司 一种含有奥氮平的药物组合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2083622B1 (no) * 1970-03-27 1975-08-22 Sankyo Co
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
GB9009229D0 (en) 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
ID21762A (id) * 1996-09-24 1999-07-22 Lilly Co Eli Formulasi partikel bersaput
US6348458B1 (en) * 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine
CA2471341C (en) * 2001-12-24 2012-01-24 Sun Pharmaceutical Industries Limited Crystalline form i of 2-methyl-4-(4-methyl-1-piperazinyl) 10h thieno [2,3-b][1,5]benzodiazepine
WO2003086361A1 (en) * 2002-04-18 2003-10-23 Dr. Reddy's Laboratories Ltd. Rapidly dispersing solid oral compositions

Also Published As

Publication number Publication date
DK1558219T3 (da) 2007-10-29
ATE374600T1 (de) 2007-10-15
DE60316714T2 (de) 2008-07-17
SI1558219T1 (sl) 2008-02-29
EP1558219B1 (en) 2007-10-03
HRP20050342B1 (hr) 2013-11-08
PL206217B1 (pl) 2010-07-30
RS51488B (sr) 2011-04-30
WO2004035027A1 (en) 2004-04-29
RS20050292A (sr) 2007-08-03
CY1107819T1 (el) 2013-06-19
US20110319395A1 (en) 2011-12-29
ES2295626T3 (es) 2008-04-16
PL376413A1 (en) 2005-12-27
DE60316714D1 (de) 2007-11-15
SI21303A (sl) 2004-04-30
AU2003269792A1 (en) 2004-05-04
EP1558219A1 (en) 2005-08-03
US20050288276A1 (en) 2005-12-29
NO20052408D0 (no) 2005-05-13
CA2502582A1 (en) 2004-04-29
HRP20050342A2 (hr) 2006-04-30
EA200500671A1 (ru) 2005-10-27
CA2502582C (en) 2010-08-03
UA89349C2 (uk) 2010-01-25
EA008516B1 (ru) 2007-06-29
PT1558219E (pt) 2008-01-04

Similar Documents

Publication Publication Date Title
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
NO2025027I1 (no) Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - forlenget.
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
DK1207756T3 (da) Anvendelse af spinosad eller en formulering, der omfatter spinosad
EP1589947B8 (en) Pharmaceutical formulation with an insoluble active agent for pulmonary administration
HUP0203451A2 (hu) Új, tuberkolózis elleni gyógyszerkészítmények és eljárás előállításukra
NO20040268L (no) Nye 2H-pyridazin-3-derivater, farmasoytiske preparater inneholdende slike og fremgangsmate for fremstilling av den aktive ingrediensen
ATE292453T1 (de) Antivirale arznei
MXPA03008420A (es) Forma farmaceutica solida oralmente dispersa.
WO2005065639A3 (en) Novel pharmaceutical compositions
MXPA05013270A (es) Forma de administracion transmucosal con irritacion mucosal reducida. reducida.
WO2005065648A3 (en) Novel drug compositions and dosage forms of topiramate
WO2004069187A3 (en) Drug formulation and delivery using crystalline methylated cyclodextrins
EA200601015A1 (ru) Пероральные композиции дезоксипеганина и их применение
TR200301553A1 (tr) İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
AU2001260089A1 (en) Pharmaceutical compositions comprising desglymidodrine as an active drug substance
NO20054417L (no) Fremgangsmate for fremstilling av farmasoytiske preperater i form av fibratholdige tabletter og de derved fremstilte tabletter
WO2004033484A3 (en) Use of stable glutamine derivatives to improve drug absorption
EA200500175A1 (ru) Соль морфин-6-глюкуронида
BR0316486A (pt) Composição farmacêutica que compreende um antagonista do ltb4 e um inibidor da cox-2 ou um inibidor combinado da cox1/2
NO20021527D0 (no) Pyrimidinderivater, fremgangsmåte for fremstilling av derivatene og legemidler inneholdende de samme som den aktivebestanddel
WO2002041875A3 (de) Verfahren zur herstellung leicht löslicher arzneimittelformulierungen und entsprechende formulierungen
HK1088213A (en) Pharmaceutical formulation with an insoluble active agent for pulmonary administration

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application